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Abstract
Erythropoietin (EPO) and its cell surface receptor (EPOR) are essential for erythropoiesis; can modulate non-erythroid target
tissues; and have been reported to affect the progression of certain cancers. Basic studies of EPOR expression and
trafficking, however, have been hindered by low-level EPOR occurrence, and the limited specificity of anti-EPOR antibodies.
Consequently, these aspects of EPOR biology are not well defined, nor are actions of polycythemia- associated mutated
EPOR alleles. Using novel rabbit monoclonal antibodies to intracellular, PY- activated and extracellular EPOR domains, the
following properties of the endogenous hEPOR in erythroid progenitors first are unambiguously defined. 1) High- Mr EPOR
forms become obviously expressed only when EPO is limited. 2) EPOR-68K plus -70K species sequentially accumulate, and
EPOR-70K comprises an apparent cell surface EPOR population. 3) Brefeldin A, N-glycanase and associated analyses point to
EPOR-68K as a core-glycosylated intracellular EPOR pool (of modest size). 4) In contrast to recent reports, EPOR inward
trafficking is shown (in UT7epo cells, and primary proerythroblasts) to be sharply ligand-dependent. Beyond this, when C-
terminal truncated hEPOR-T mutant alleles as harbored by polycythemia patients are co-expressed with the wild-type EPOR
in EPO-dependent erythroid progenitors, several specific events become altered. First, EPOR-T alleles are persistently
activated upon EPO- challenge, yet are also subject to apparent turn-over (to low-Mr EPOR products). Furthermore, during
exponential cell growth EPOR-T species become both over-represented, and hyper-activated. Interestingly, EPOR-T
expression also results in an EPO dose-dependent loss of endogenous wild-type EPOR’s (and, therefore, a squelching of
EPOR C-terminal- mediated negative feedback effects). New knowledge concerning regulated EPOR expression and
trafficking therefore is provided, together with new insight into mechanisms via which mutated EPOR-T polycythemia alleles
dysregulate the erythron. Notably, specific new tools also are characterized for studies of EPOR expression, activation, action
and metabolism.
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Introduction
Hematopoietic growth factors (HGF), and their cognate
receptors (HGF-R’s), exert prime regulation over stem, progenitor
and peripheral blood cell levels [1,2,3]. Factors that regulate HGF-
R expression, and cell surface receptor trafficking, are therefore
of central importance for balanced hematopoiesis. Regulation
over HGFR expression is dynamic, and can occur via diverse
mechanisms. As recent examples, alternate splicing of c-KIT and
IL3R-alpha can alter PI3K/AKT signaling [4,5], while miR-155
targeting of IL13R-alpha1 receptors can divert macrophage to an
M2/pro-Th(2) fate [6]. Dysregulated cell surface receptor
expression also is associated with hematopoietic malignancies.
To illustrate, IL7R-alpha, IL3R-alpha and c-KIT cell levels are
dysregulated in adult ALL [7], AML progenitors [8], and AML1-
ET09a [9]. Mutations in HGF receptors also occur that alter
signal transduction capacities, and function. As one example, stop
codon mutations in exon-10 of the thrombopoietin receptor
enhance JAK/STAT signaling in a myeloproliferative disease
context [10]. Such HGF-R mutations that give rise to C-terminal
truncated receptor forms are also of broader occurrence. Alleles of
GCSFR that encode such mutations, as a second example, are
associated with congenital neutropenia [11], as well as hemato-
poietic stem cell hyper-expansion [12].
For the erythropoietin receptor (EPOR), a number of single-
allele stop-codon mutations (predominantly in exon-8) have been
described in association with primary familial and congenital
polycythemia (PFCP) [13,14,15]. Such EPOR mutations often
result in the loss of not only a C-terminal site for p85/p110 PI3K
recruitment, but also PY motifs indicated to recruit one or more
negative regulators as SOCS-1, SOCS-3 and/or SHP1 phospha-
tase [16,17]. Such EPOR truncations (‘‘EPOR-T’’ alleles), how-
ever, also may disrupt sites for EPOR internalization, ubiquitina-
tion, endosome trafficking and/or lysosome plus proteosomal
processing. Uncertainty therefore exists concerning mechanisms of
EPOR-T dysregulation. For the endogenous wild-type EPOR,
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with recent arguments made, for example, for ligand- independent
[18] vs dependent- trafficking [19]. Studies of BTRC E3 ubiquitin
ligase docking [20], cytoplasmic lysine mutations [21] and p85-
alpha recruitment [19] have begun to provide insight into
regulated EPOR transit, and have implicated the existence of
interestingly complex mechanisms that regulate EPOR pools. In
addition, studies in related IL5R and IL7R systems recently have
suggested roles for endosome entry [22,23] during HGF-R
activation.
Towards better understanding EPOR trafficking properties, as
well as properties of EPOR mutants harbored by PFCP patients,
we presently have developed a novel panel of rabbit monoclonal
antibodies to the hEPOR, and have used these new tools to study
wild-type and truncated human EPOR expression, distinct
molecular-weight forms, subcellular localization, activation, and
trafficking in EPO- dependent human erythroid progenitor cell
models. Our investigations first demonstrate dynamic, highly
ligand- dependent EPOR trafficking to the extent that simple
maintenance of cells in EPO essentially depletes EPOR’s from the
cell surface. Second, (and in contrast with certain prior studies)
[18,24], only a limited apparent intracellular EPOR pool is
detected (and exists as a core-glycosylated EPOR-68K form).
Third, truncated EPOR receptor forms appear to be only
modestly attenuated in their EPO-induced internalization, but
under physiological conditions accumulate as mature EPOR-T
forms which further become persistently activated (in an EPO
dose-dependent fashion). Interestingly, the expression of such
truncated EPOR forms also markedly decreases endogenous wild-
type EPOR levels. Overall, the present studies provide new insight
into EPOR expression dynamics, as well as complex mechanisms
via which mutated EPOR alleles can contribute to polycythemia.
New tools also are advanced for studies of EPOR expression,
activation, action mechanisms and trafficking.
Materials and Methods
Cell lines, and primary erythroid progenitor cells
UT7epo cells [25] were maintained in HEPES-buffered IMDM
containing 10% FBS plus 3 U/mL EPO (Epoetin-alfa, OrthoBio-
tech, Raritan, NJ). HL-60 cells (ATCC, Manassas, Virginia) were
maintained in IMDM plus 20% FBS. Media and FBS were from
Invitrogen (Carlsbad, CA). In cytokine withdrawal experiments,
washed cells were cultured for defined intervals in IMDM
containing 0.2% BSA, 0.1 mM 2-mercaptoethanol, and 10 mg/
mL holo-transferrin. Brefeldin-A (Sigma #B5936, St Louis, MO)
was used at 7.5 mg/mL (0.1% DMSO, 20-hour exposure). Human
bone marrow CD34
pos-derived (pro)erythroblasts (Lonza) were
expanded in StemPro34 medium (Invitrogen) supplemented with
100 ng/mL rhSCF, 20 ng/mL rhIL3, 20 ng/mL rhIL6, 100 ng/
mL rhFLT3, 2.5 U/mL EPO, 0.1 mM beta estradiol and 1 mM
dexamethasone. Cells were seeded at 3.5610
6 cells per mL. On
days 1.5, 4.5, 7.5 and 10.5, one-volume of fresh medium was
added. On days 3, 6, 9 and 12, 90% of medium was replaced.
EPOR antibodies
EPOR antibodies were generated (in collaboration with Epi-
tomics,Burlingame,CA)byimmunizingrabbitswitharecombinant
hEPOR extracellular domain, or with KLH-coupled EPOR G334–
L350peptides[G
336SEHAQDT-(P)-YLVLDKWL
351].Followinga
fifth boost, antigen specific immune responses were initially
evaluated by ELISA (using phosphorylated and non-phosphorylat-
ed peptides). Rabbits with robust responses were used to generate
hybridomas, and monoclonal antibodies. Select MAb-secretory
hybridomas were expanded, and secreted IgG antibodies were
purified by affinity chromatography (Protein-A-Sepharose CL4B)
(Sigma).
EPOR constructs and retroviral transduction
Using a wild-type human EPOR cDNA as a template, mutated
cDNAs were prepared to correspond to those harbored by two
characterized families with primary familial and congenital
polycythemia [13,14]. Each mutation is within exon-8, and each
introduces a premature translational stop codon. Specific mutations
are G5881T, and G1251T [13,14]. Encoded truncated receptors
(EPOR-T’s) therefore lack 110 and 92 C-terminal amino acid
residues respectively; include Y285 and Y344 residues in their
mature forms; and are designated as EPOR-T374, and EPOR-T-
392. Mutagenesis was accomplished using a Quick-Change XL
system (Stratagene, Santa Clara, CA). Products were sequenced on
each strand, and cDNAs were cloned to pMSCVneo (Clontech,
Mountain View, CA). VSV-G packaged pMSCVneo retroviruses
then were prepared as described [26], and were concentrated (12.5-
fold) using a PEG method (SBI #LV810A-1, Mountain View, CA).
UT7epo cells were then transduced at varied MOI’s (3-fold dilution
series). Specifically, exponentially growing cells were plated at
1610
5 cells/mL (0.5 mL, 12-well format). Polybrene (8 ug/mL)
and virus then were added stepwise. At 20 hours, cells were
transferred to 1 mL of fresh medium and cultured for 24 hours.
During subsequent expansions, G418 selection was applied
(0.9 mg/mL). An essentially equivalent approach was used to
transduce HL60 cells (0.8 mg/mL G418 selection).
Flow cytometry
For flow cytometry, cells were washed and resuspended in 4uC
PBS, 0.1% BSA containing 0.3 mg/mL Fc blocker (Stem Cell
Technologies #01470, Vancouver, BC). After 5 minutes of
incubation (4uC), hIgG was added (50 mg/mL, 15 minutes). Cells
were then incubated for 1 hour at 4uC with primary anti-EPOR
antibodies (typically, 1.0 mg/0.2 mL). Washed cells were next
incubated at 4uC for 30 minutes with 0.1 mg/mL Alexafluor-647
goat anti-rabbit IgG (Invitrogen #A21245, Carlsbad, CA) in PBS,
0.1% BSA. For hCD34
pos- derived cells, transferrin receptors and
glycophorin-A levels were assayed using FITC-anti-TFR, and PE-
anti-GPA antibodies (BD Biosciences). Equivalent numbers of
gated events were then analyzed (BD Biosciences FACScalibur
flow cytometer, CellQuest Pro software) [27].
Western blot analyses
Cell lysate preparations, SDS-PAGE, western blotting and ECL
were as described previously [26,27]. Endoglycosidase-F (New
England Biolabs, Ipswich, MA) was used as prescribed (25,000 U/
mL, 37uC, 3 hours). Commercial primary antibodies were from
Cell Signaling Technology (Danvers, MA) and included anti-
JAK2 (#3230), anti- PY1007/1008 JAK2 (#3776), and anti- beta
tubulin (#2128). Signals were analyzed quantitatively using
Image-J software (http://rsb.info.nih.gov/ij/). Immunoprecipita-
tions used 0.4% Igepal cell lysates, 2610
7 cells per sample, and
4 mg of designated anti-EPOR antibodies. Immune complexes
were retrieved using Protein-A Sepharose CL4B.
RT-PCR
Cells were lysed directly in Trizol reagent, and RNA was
isolated as previously detailed [26,27]. Quantitative RT-PCR
utilized iQ SYBR Green reagent [26,27], a BioRad i-cycler
(Model iQ5) (BioRad, Hercules, CA), and hEPOR and beta-actin
primers from SuperArray (cat # PPH02642A and PPH00073E).
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For immunohistochemistry (IHC) cell pellets were prepared by
rapidly freezing centrifuged cell pellets (dry ice). Cell pellets were
then dislodged from tubes; mounted (cryomold with OCT
compound) (Sakura Finetek, Torrance, CA); and immediately
frozen (dry ice/isopentane). Sections (5 mm) were then cut (Leica
CM1950 cryostat) (Bannockburn, IL), mounted on glass slides, and
fixed (4% paraformaldehyde, 10 minutes). Endogenous peroxi-
dases were inhibited with Peroxidazed-1 (BioCareMedical,
Concord, CA), and background was blocked (Background Sniper,
BioCareMedical). Tissue sections were then stained with primary
antibody (5 mg/mL, 30 minutes) plus Mach2 rabbit polymer
(BioCareMedical). This was followed by development with 3,39-
Diaminobenzidine (DAB, BioCareMedical) for primary antibody
detection. Slides were counter-stained with hematoxylin, followed
by dehydration with graded alcohol. Slides were mounted with
Entellan mounting media (Electron Microscopy Sciences, Hatfield,
Pa), and visualized with a Leica DM2500 microscope plus LAS
software (Leica).
Results
EPO- exposure sharply limits the expression of high
molecular weight hEPOR forms
Studies of the regulated expression, and trafficking, of the
hEPOR have been hampered due to low-level expression of
endogenous EPOR’s [28,29] and by the limited specificity of anti-
EPOR antibodies [30]. To advance such studies, we first prepared
novel rabbit monoclonal antibodies against an hEPOR membrane-
proximal cytoplasmic motif (G
336SEHAQDTYLVLDKWL
351)
(Figures 1A, 1B). Antibodies from several select clonal hybridomas
(as generated from rabbits immunized with this EPOR epitope)
proved to exhibit high specificity, and sensitivity. In Figure 1C, this
is demonstrated via experiments in which myeloid HL60 cells were
transduced at limiting MOI’s with VSV glycoprotein-packaged
pMSCVneo retroviruses encoding the wild-type hEPOR, or one
(G5881T) or another (G1251T) naturally occurring C-terminal
truncated EPOR allele. Within lysates prepared from these HL60-
EPOR lines, predominant EPOR forms detected by western
blotting (with designated MAb ‘‘IC-c1.1’’) corresponded to the
predicted full-length products of WT-EPOR, EPOR-T-392 or
EPOR-T-374 alleles (i.e., ,68 K, 48 K and 42 K). As estimated by
flow cytometry and western blotting, ectopic EPOR expression
levels in these HL60-EPOR lines was between 20% to 60% of
endogenous EPOR levels in UT7epo cells (data not shown). EPOR
antibody IC-c1.1 was not reactive with proteins from HL60 cell
lysates. (For comparison, properties of additional, but not fully
specific anti-EPOR monoclonal antibodies also are illustrated in
Figure S1).
Next, using anti-EPOR antibody IC-c1.1, dynamics of endog-
enous EPOR expression were assessed in exponentially growing
EPO- dependent human erythroid UT7epo cells. Somewhat
unexpectedly, only limited levels of high Mr EPOR forms were
detected and instead, a Mr ,36 K EPOR species predominated
(Figure 1D, right lane). In contrast, when EPO was withdrawn,
substantial increases in levels of high Mr EPOR forms resulted
(Figure 1E). When cells subsequently were re-exposed to EPO
(3 U/mL, 15 minutes) a slower migrating higher Mr EPOR form
was observed (Figure 1E, right lane). Levels of Mr ,36 K and
40 K processed EPOR forms also increased, which are proposed
to correspond to processed apparent EPOR turnover products.
These initial experiments indicated that endogenous EPOR
levels in human erythroid progenitor cells might be markedly
subject to ligand regulation. This concept was assessed further in
experiments that examined time-component effects of limiting
EPO on EPOR expression. At staggered intervals UT7epo cells
were washed, replated in the absence of EPO, and cultured for 5,
10 or 20 hours prior to lysate preparation and western blotting for
EPOR forms. As one control, EPO was added back (included) in
cultures of washed and re-plated cells (‘‘EPO addition’’). In
addition, at the end of each time interval of EPO- withdrawal, cells
were challenged with EPO (3 U/mL) for 15 minutes prior to lysis
(‘‘EPO stimulation’’). At 5, 10 and 20 hours of culture in the
absence of EPO, major increases in levels of a Mr ,68 K EPOR
form first were observed (Figure 1F). Although challenging to
resolve, at 20 hours (especially) a discrete Mr ,70,000 EPOR
species also formed in the absence of EPO (Figure 1F, 20 hr time-
frame, center lane). Subsequent brief exposure to EPO (15 min-
utes, 3 U/mL) selectively converted this Mr ,70 K species to an
activated Mr ,72 K EPOR form (Figure 1F, right-most lane).
Therefore, the limiting of EPO leads to an accumulation of
EPOR-68K and EPOR 70K forms (which otherwise comprise
rare EPOR species, especially EPOR-70K).
For antibody IC-c1.1, additional data in support of specificity in
western blots was provided by the ability of immunizing peptide to
block the detection of the endogenous EPOR species in UT7epo
cells (Figure S2). In addition, the utility of three anti-EPOR
antibodies (IC-c1.1, IC-c34.11 and EC-c38.5) in immunoprecip-
itation assays was initially demonstrated (Figure S3) as was the
application of antibody IC-c1.1 in IHC (Figure S4).
hEPOR expression at the cell surface, and EPOR
internalization, are markedly ligand-dependent
To enable direct analyses of EPOR expression at the cell
surface, rabbit monoclonal antibodies to the EPOR extracellular
domain were prepared, and assessed for utility and specificity in
flow cytometry. Three such antibodies proved to be sensitive, and
highly specific. In the present studies, one such EPOR MAb
(designated ‘‘EC-c38.5’’) was used. Figure 2A illustrates specificity
first by the assay of cell surface EPOR’s on UT7epo cells following
EPO withdrawal as compared directly to myeloid HL60 cells (left
panel); and second via staining of UT7epo cells (following EPO
withdrawal) with MAb EC-c38.5 (vs a negative control of rabbit
IgG) (right panel).
Effects of EPO withdrawal on endogenous cell surface EPOR
expression in UT7epo cells were next further analyzed. At 6 hours
of EPO withdrawal, moderate increases in cell surface EPOR
expression were detected, but levels substantially increased further
at 24 hours of EPO withdrawal (Figure 2B). EPO effects on EPOR
down-modulation also were studied. At 30 minutes of EPO-
exposure, a clear dose-dependent effect on cell surface EPOR
down-modulation was observed (Figure 2C). In related time-
course analyses, when EPO-deprived UT7epo cells were chal-
lenged with EPO at a fixed concentration of 3 U/mL, .90% of
EPOR’s were lost from the cell surface by 30 to 90 minutes of
exposure (Figure 2D). These studies are consistent with western
blot analyses (see above, Figures 1D, E, F); reinforce a case that
EPOR trafficking is strongly ligand-dependent; and also at least
suggest (by correlation) that EPOR-70K species corresponds to a
cell surface- resident EPO receptor pool.
To further establish the property of stringent ligand- depen-
dency for cell surface EPOR expression, endogenous EPOR
expression in primary human bone marrow CD34
pos- derived
erythroid progenitors also was studied. As observed for UT7epo
erythroid progenitors, withdrawal of EPO resulted in multi-fold
increases in mean levels of EPOR expression (Figure 2E, left
panel). When exposed to EPO at limiting concentrations (during
overnight culture), cell surface EPOR levels on primary pro-
Dynamic Regulation of EPOR Pools
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concentration- dependent fashion (Figure 2E, right panel). To our
knowledge, this is the first report that allows for analyses of
endogenous EPOR trafficking in primary human bone marrow
proerythroblasts. In further support of these studies, western blot
(and RT-PCR) analyses were performed. These studies indicated
persistent expression of the hEPOR in both early and late GPA
high
as well as GPA
low proerythroblasts (Figure S5).
Defining the nature of endogenous EPOR Mr species
In examining effects of limited ligand availability on EPOR
expression, we observed an apparent time-dependent increase first
for an EPOR-68K receptor form, and at later time-points for an
apparent EPOR-70K EPOR form (see above: Figure 1F, lane 1 vs
lanes 3, 6, 9). Initial EPO- exposure experiments also at least
suggested that EPOR-70K may correspond to a cell surface
species, while EPOR-68K might represent an intracellular EPOR
precursor pool. To better define the nature of observed major
EPOR forms, extended EPO withdrawal- and exposure- exper-
iments were performed (with gradient gels plus overnight
electrophoresis employed in western blot analyses). At 20 hours
post EPO- withdrawal, EPOR-68K and EPOR-70K forms each
became clearly represented, together with a lower Mr EPOR-36K
form (Figure 3A, lanes 1 and 5). Upon EPO exposure, EPOR-70K
was selectively lost, and an EPOR-72K species rapidly formed
(during an apparent conversion to activated EPOR’s). Possible
effects of including FBS during EPO- withdrawal (and exposure)
also were tested, but EPOR expression patterns were not altered
(Figure 3A, right lanes). EPO- exposure also generated a Mr 40 K
EPOR-form, which together with EPOR-36K are indicated to
represent EPOR turnover products. These results were reproduc-
ibly observed when either 1 U/mL or 3 U/mL EPO was used in
EPO-challenge experiments (Figure 3B, upper panel) (note: 3 U/
mL is required to maintain exponential growth and full viability of
UT7epo cells). A quantitative summary of EPOR-70K, -72K and
-68K expression as observed in these time-course and EPO-dosing
experiments is also provided (with normalization to maximum
levels observed for EPOR-72K) (Figure 3B, lower panel).
In further studies of EPOR forms (and their possible inter-
relatedness), effects of brefeldin-A and/or N-glycanase were
analyzed (Figure 4). When UT7epo cells were exposed to
brefeldin-A (an inhibitor of ER and golgi compartmentalized
guanine nucleotide- exchange factors as involved in Arf1p-
dependent transport) [31], an EPOR-68K form predominated.
In addition, and in-keeping with the notion that EPOR-68K may
comprise an intracellular EPOR pool, little to no conversion of
EPOR-68K to higher Mr forms was observed upon EPO-
exposure (Figure 4A). In addition, following brefeldin-A exposure
and post- EPO withdrawal, UT7epo cells did not express
detectable cell surface EPOR’s; and did not respond to EPO with
ERK1,2 activation (PT-202, PY-204 phosphorylation) (Figure 4B).
Finally, lysates prepared from brefeldin-A (or DMSO-) exposed
UT7epo cells were treated with N-glycanase (+/2 PNGase F)
prior to western blot analyses in order to assess whether EPOR-
68K might represent an aglycosyl precursor. Interestingly, EPOR-
68K (as well as EPOR-70K and -72K species) proved to be core-
glycosylated (PNGase F sensitive), and lessened in apparent Mr by
,2 K due to PNGase F treatment (‘‘EPOR-66K’’) (Figure 4C).
Taken together, the above work allowed for the framing of models
for the stringently regulated expression, and trafficking, of the
endogenous hEPOR at limiting vs elevated EPO levels (Figure 5).
Specifically, when (and only when) EPO becomes limiting, core-
glycosylated apparent intracellular EPOR-68K pools first increase
(Figure 5, left panel). Subsequently, EPOR-70K species are
proposed to populate the cell surface, and become available for
ligation. In the absence of EPO, a portion of high Mr EPOR forms
nonetheless appear to be subject to ligand-independent turnover,
in part, to proposed EPOR-36K and 40 Kspecies. When EPO
levels increase (e.g., due to anemia or anti-anemia therapy)
(Figure 5, right panel), cell surface-resident EPOR’s rapidly (and
transiently) convert to activated EPOR-72K species. Over a 30 to
90 minute time-course, EPOR’s are then depleted from the cell
surface in a ligand-dependent fashion and are processed (at least in
part) to Mr 40 K and 36 K EPOR forms. (For the latter, it is
noted that direct evidence has not yet been provided that these low
molecular weight forms derive from ligand-activated EPOR
complexes).
Mechanisms underlying dysregulated erythroid
progenitor cell expansion due to polycythemia-
associated hEPOR mutations
Mutations in the EPOR that occur most frequently within exon
8 [13,14,15] can lead to premature stop codon utilization, and
therefore co-expression of wild-type plus C-terminal truncated
EPOR forms (designated ‘‘EPOR-T’s’’) (Figure 6A). One such
recently described mutation is EPOR- G5881T [13] which
encodes EPOR-T-392. Another is EPOR- G1251T [14], which
encodes EPOR-T-374. To study how the truncation of such
alleles might affect EPOR trafficking (and upstream signaling),
pMSCVneo vectors encoding EPOR-T-392 and EPOR-T-374
EPOR alleles were used to stably transduce UT7epo cells at
limiting MOI’s. As an additional control (and to account for
modest increases in overall EPOR levels) UT7epo cells also were
transduced (in parallel at matched, limiting MOI’s) with a wild-
type hEPOR construct (WT-EPOR). As shown (for the wt-EPOR)
Figure 1. Initial defining of endogenous EPOR forms (Mr species), and expression dynamics related to EPO exposure. A] Schemata of
the human EPOR – Features include extracellular and transmembrane regions (EC, TM); box 1,2 JAK2 association site; cytoplasmic phosphotyrosine
(PY) motifs; candidate lysine (K) residues for ubiquitination; and a S462 BTRC E3 ligase interaction site. B] hEPOR epitope used to produce antibodies
to an intracellular domain (EPOR anti-IC monoclonals). C] Specificity of antibody IC-c1.1 – Among antibodies generated against an EPOR peptide
immunogen, several proved sensitive and specific in western blotting. For antibody IC-c1.1, specificity is illustrated using lysates from myeloid HL60
cells transduced at limiting MOI with pMSCV retroviruses encoding the wild-type EPOR, or truncated T-EPOR alleles EPOR-T374 or EPOR-T392. D] EPO-
dependent erythroid progenitor cells in exponential growth-phase exhibit only minor levels of high-Mr EPOR’s – Using antibody IC-c1.1, EPOR levels
(and Mr species) in exponentially growing UT7epo cells initially were assessed. Total cell lysates prepared in parallel from human myeloid HL60 cells
served as a negative control. In UT7epo cells, low-Mr EPOR species predominate, with only minor levels of high Mr EPOR species detected. E] EPO-
withdrawal and -challenge experiments indicate the formation of higher-Mr EPOR species when EPO is limiting (and when EPOR
pos cells are
challenged by EPO) – UT7epo cells were cultured for 24 hours in the absence of EPO, and then exposed to EPO (3 U/mL) for 0, or 15 minutes (center
and right lanes). For comparison, EPO levels (and species) in exponentially growing UT7epo cells also were co-analyzed (left lane). F] Time-course of
the formation of EPOR-70K receptors under limiting-EPO conditions, and EPO-induced conversion to activated EPOR-72K species – Exponentially
growing UT7epo cells were transferred to IMDM, transferrin (10 ug/mL), 0.2% BSA, 0.1 mM 2-mercaptoethanol and cultured for the indicated
intervals (time-points). For comparison, subcultures received EPO (‘‘EPO addition’’). Where indexed, cells subsequently were challenged with EPO
(3 U/mL) for 15 minutes (‘‘EPO stimulation’’). Lysates then were prepared, and analyzed by western blotting.
doi:10.1371/journal.pone.0029064.g001
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approximated those of the endogenous EPOR. Importantly, it also
was possible to discern Mr species formed by EPOR-T alleles
within a background of the endogenous wild-type EPOR (e.g., via
densitometry scanning) (see Figure S7 for an example of EPOR-T-
392). (Note: In polycythemia patients harboring truncated EPOR
forms, a normal wild-type EPOR allele typically is also expressed)
[13,14,15]. As analyzed for the polycythemia- associated EPOR
allele EPOR-T-392, an additional observation was an apparent
lack of any major EPO- refractive EPOR-T species (i.e.,
potentially corresponding to an intracellular pool).
Using UT7-EPOR-T-392 cells, kinetics of EPOR and truncated
EPOR-T allele activation next were directly assessed. This was
made possible by our development of a novel rabbit monoclonal
antibody to PY344- activated hEPOR’s. When cells and lysates as
defined in Figure 6B were analyzed (within an HGF-withdrawal
plus EPO-stimulate paradigm) for levels of activated EPOR’s, one
obvious result was that the truncated allele EPOR-T-392
remained persistently activated for $90 minutes post- EPO
exposure (Figure 7A, including quantitative analyses in lower
panels). By direct comparison, PY-activation of the wild-type
EPOR peaked within 10 minutes of EPO exposure and
subsequently decayed. Further evidence for sustained activation
of the truncated allele EPOR-T-392 (and its complexed co-factors)
was provided by analyses of JAK2 activation (PY1007, PY1008
phosphorylation). In particular, in UT7-EPOR-T-392 cells, EPO-
exposure also led to not only the sustained stimulation of JAK2,
but also to increased intensities of PY-JAK2 activation (as observed
at both 0.8 U/mL, and 3.2 U/mL EPO)(Figure 7B).
A final set of experiments focused on effects of truncated
EPOR-T allele expression on EPO receptor expression, and
activation, under conditions of continuous UT7epo cell culture in
the presence of EPO (at 0.3 or 3.0 U/mL). This approach
contrasts with the above EPO withdrawal-and-stimulate design
(e.g., Figure 7). Each, however, is physiologically relevant in that
EPO levels in vivo can flux $1000-fold [18]. In these experiments,
three notable results were uncovered. First, levels of high- Mr wild-
type EPOR forms decreased in UT7-WT-EPOR cells due to
heightened EPO dosage, while levels of truncated EPOR forms in
both UT7-EPOR-T-392 and UT7-EPOR-T-374 increased (or
stayed the same) with EPO dosage (Figures 8A and 8B). Second,
and likewise in an EPO dose-dependent fashion, the expression of
truncated EPOR forms (EPOR-T-392 or EPOR-T-374) interest-
ingly resulted in obvious decreases in levels of the co-expressed
endogenous wild-type EPOR (Figures 8A and 8C). Third (and
again somewhat unexpectedly) EPO dose-dependent turnover
of truncated alleles to low Mr 24 K and Mr 22 K species
(respectively) was obvious (Figure 8D) (despite prior hypotheses
that internalization of such truncated EPOR alleles might be
disabled) [15].
Using our anti- EPOR-PY344 antibody, cells and lysates as
studied above (Figure 8) were analyzed for levels of activated
EPOR forms. Interestingly, truncated EPOR alleles (EPOR-T-
392, EPOR-T-374) proved to be chronically activated (PY-344
phosphorylated) (Figures 9A), and disproportionately so as
compared to overall EPOR expression patterns. Apparent
proposed degradation products as Mr 24 K and 22 K species as
derived from truncated EPOR-T-392, and EPOR-T-374 alleles
also were obvious. For the wild-type EPOR, in contrast, only
limited levels of activated high-Mr PY-EPOR forms were detected
(and Mr ,38 K and 45 K species predominated) (Figures 9A). In
UT7-WT-EPOR, UT7-EPOR-T-392 and UT7-EPOR-T-374
cells, JAK2 activation also was assessed. In cells expressing C-
terminal truncated EPOR alleles, JAK2 PY-phosphorylation (at
PY1007, 1008) proved to be chronically elevated (Figure 9B). For
EPOR-T expressing UT7epo cells, advantages in EPO-dependent
expansion also were observed (Figure 9B, right panel and data not
shown).
Based on overall findings, a model is outlined in which multiple
mechanisms are suggested to contribute to gain-of-function
properties of polycythemia-associated C-terminally truncated,
EPOR mutant alleles (Figure 10). First, unlike the wild-type
EPOR, EPOR-T alleles do not appear to accumulate (or occur) as
an obvious intracellular pool (component mechanism 1). Second,
based on persistent expression and chronic activation as mature,
activated forms, EPOR-T alleles are proposed to be attenuated in
their internalization and/or trafficking through lysosomes (com-
ponent mechanisms 2, 3, 4). As implicated via previous studies
[16,17,32,33,34,35], EPOR-T alleles also are less susceptible to
feedback inhibition by SOCS1,3 and/or SHP1 phosphatase
(component mechanism 5). In addition, co-expression of EPOR-
T forms together with the endogenous wild-type EPOR (as in
polycythemia patients) interestingly leads to a substantial decrease
in levels of full-length EPOR’s (component mechanism 6).
Discussion
Central biological properties of hematopoietic growth factor
receptors include regulated expression, cell surface residency and
internalization features. These can be diverse, and are important
to understand within contexts of defining cytokine target tissues
and cells; possible effects of cytokine dosing on receptor up- and/
or down- modulation; distinct routes engaged by growth factor
agonists, mimetics or antagonists; and possible dysregulation of
such receptor properties due to mutation or skewed expression.
Among HGFR’s, EPOR complexes present a clinically relevant
Figure 2. EPOR expression at the cell surface depends sharply upon the history of EPO- exposure. A] Cell surface EPOR detection using
antibody EC-c38.5 – Among rabbit monoclonal antibodies generated against an hEPOR ECD, several proved sensitive and specific in flow cytometry
assays (Alexafluor 647 second antibody detection). For EC-c38.5, this is illustrated by assays of endogenous EPOR’s on UT7epo cells, here following
brief EPO withdrawal (8-hours). Negative controls included myeloid HL60 cells, and non-immune rabbit IgG. B] Low ligand levels allow for EPOR
expression at the cell surface – In UT7epo cells, cell surface EPOR levels were assayed at 6 hours or 24 hours following EPO withdrawal (and were
compared to levels detected during exponential growth in EPO). C] Effects of exposure to EPO at varied concentrations on EPOR internalization also
were assessed (at 30 minutes of exposure). D] EPO exposure essentially depletes cell surface EPOR’s – UT7epo cells were cultured without EPO for
20 hours. Cell surface EPOR levels were then assayed through time following EPO exposure (3 U/mL). E] Specific detection of cell surface EPOR
expression in developing human CD34-derived primary erythroid progenitors – Left panel: Primary erythroid cells were expanded from human BM
CD34
pos cells in StemPro34 medium containing SCF (100 ng/mL), IL3 (20 ng/mL), IL6 (20 ng/mL), FLT3 (100 ng/mL), EPO (2.5 U/mL), 0.1 mM beta-
estradiol and 1 mM dexamethasone. For cell populations generated at 10.5 days of expansion, and following 12 hours of HGF withdrawal, cells then
were exposed (+/2) to EPO for 30 minutes; adjusted to 2uC; and assayed by flow cytometry for levels of cell surface EPOR expression (anti-EPOR
antibody EC-c38.5). Myeloid HL-60 cells served as a non-specific binding control. Right panel: Exposure to EPO during HGF withdrawal at doses as low
as 0.25 U/mL proved to rapidly down-modulate cell surface EPOR’s (for comparison, effects of 15-minute exposure to EPO at 2 U/mL post HGF-
withdrawal on EPOR levels were co-analyzed).
doi:10.1371/journal.pone.0029064.g002
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PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e29064system that continues to serve as an important paradigm. To
illustrate, the EPOR was first to be directly associated with Janus
kinase action [36]; the first HGF-R to be understood to transduce
trans-membrane conformational signaling events [37]; and among
the first to be defined as a target of SOCS plus SHIP negative
regulators [38,39]. Recently, new impetus to further advance an
understanding of EPOR properties has been brought to bear. This
includes the emergence of new EPOR agonists [40] as well as
apparent EPOR- cytoprotective effects on vascular [41], retinal
[42] and pancreatic beta- cells [43]. This is being met with
continued new discoveries, including reports on Lnk protein [44]
and transferrin receptor-2 [45] as novel transducers of EPOR
Figure 3. Initial defining of proposed intacellular, cell surface and ligand- activated EPOR forms. A] Apparent conversion of an EPOR-
70K form (but not an EPOR-68K form) to an activated EPOR-72K species– UT7epo cells were cultured for 20 hours in the absence of EPO (and absence
or presence of 10% FBS). Cells then were challenged with EPO (3 U/mL). At the time-points indicated, lysates were prepared, and analyzed for EPOR
forms by western blotting. B] Time- dependent, and EPO dose- dependent formation of EPOR-70K and EPOR- 72K species- UT7epo cells were
cultured for 20 hours in the absence of hematopoietic growth factors (to give rise to EPOR-68K and -70K species). Cells then were challenged with
EPO at either 1 U/mL (left panels) or 3 U/mL (right panels). At 0, 8, 24 and 72 minutes of EPO exposure, lysates were prepared and analyzed by
western blotting for EPOR forms. Kinetics of EPOR-70K loss, and EPOR-72K formation as induced by lower-dose EPO were similar to higher-dose EPO.
Composite data for effects of EPO on EPOR-70K, EPOR-72K and EPOR-68K forms are also summarized quantitatively (lower panel). Values (mean
expression levels) are normalized to maximal levels of activated EPOR-72K species observed. (Also note the apparent lack of EPO-effects on levels of
EPOR-68K).
doi:10.1371/journal.pone.0029064.g003
Figure 4. EPOR-68K species correspond to a brefeldin-resistant, endoglycosidase F- sensitive intracellular EPOR pool. A] Brefeldin-A
effects on endogenous EPOR forms – UT7epo cells were cultured without EPO for 16 hours, and then for 20 hours in the presence or absence of
brefeldin A (65 ug/mL, 0.1% DMSO) with EPO at 0, 0.2 or 0.8 U/mL. Lysates then were prepared and analyzed for EPOR forms. Exponentially growing
cells (+/2 brefeldin A) also were co-analyzed. In the right panel, relative levels of EPOR-68K were quantitatively estimated. B] Brefeldin-A inhibits cell
surface EPOR expression and ERK1/2 activation– Upper panel: Following EPO-withdrawal, and [+]v s[ 2] brefeldin-A exposure, levels of cell surface
EPOR expression were assayed. Lower panel: For cells cultured without EPO and +/2 brefeldin-A, subpopulations were challenged with EPO
(15 minutes). Lysates were then analyzed for levels of phosphorylated ERK1, 2. C] EPOR-68K is an endoglycosidase F- sensitive, apparent core
glycosylated species– UT7epo cells were cultured in the absence of EPO for 20 hours +/2 brefeldin A. Each treatment group was then exposed to
EPO (0 or 15 minutes). Lysates were prepared, treated with endoglycosidase-F (i.e. N-glycanase) and analysed by western blotting (antibody IC-c1.1).
doi:10.1371/journal.pone.0029064.g004
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PLoS ONE | www.plosone.org 9 January 2012 | Volume 7 | Issue 1 | e29064Figure 5. Framing a basic model for endogenous EPOR trafficking. Left panel: Data in Figures 1, 2, 3 and 4 indicate that conditions of low
level EPO provide for increases in intracellular EPOR-68K and cell surface EPOR-70K pools. Right panel: This poises targeted cells for a rapid response
to EPO. Ligand-induced EPOR turnover to 40 K and 36 K forms also occurs. A subpopulation of EPOR’s also undergoes constitutive turnover.
doi:10.1371/journal.pone.0029064.g005
Figure 6. Balanced ectopic expression of the polycythemia- associated EPO receptor allele EPOR-T-392 in UT7epo cells. A] PFCP-
associated truncated EPOR-T forms are diagrammed, together with the wild-type (wt) hEPOR. B] UT7epo cells were transduced at matched, low MOI’s
with VSVg- packaged retroviruses encoding EPOR-T-392 or, as a control for overall EPOR expression levels, the wild type EPOR (wt-EPOR). Stably
transduced UT7-wtEPOR and UT7-EPOR-T-392 cells were cultured for 20 hours in the absence of EPO. Upper panel: Cells were then exposed to EPO
(0.8 U/mL). At 0, 10, 30 and 90 minutes, lysates were prepared and analyzed by western blotting for levels of EPOR’s. Lower panel: Analyses were as
above, but with an increased EPO challenge of 3.2 U/mL.
doi:10.1371/journal.pone.0029064.g006
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PLoS ONE | www.plosone.org 10 January 2012 | Volume 7 | Issue 1 | e29064Figure 7. Upon EPO ligation, the polycythemia-associated truncated EPOR allele EPOR-T-392 exhibit sustained activation. A, B] UT7-
wtEPOR and UT7-EPOR-T-392 cells were cultured for 20 hours in the absence of EPO. Cells were then exposed to EPO at 0.8 U/mL (left panel), or
3.2 U/mL (right panel). At 0, 10, 30 and 90 minutes, lysates were prepared and analyzed by western blotting for levels of PY344- EPOR (panel A).
Levels of activated JAK2 also were determined (panel B). PY-EPOR and PY-JAK2 levels also were quantitatively estimated (panel B, lower sub-panels).
doi:10.1371/journal.pone.0029064.g007
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understanding basic EPOR properties, the present study focuses
first on defining the nature of distinct EPOR forms, their
interrelatedness, and an unresolved question of the extent to
which EPOR expression at the cell surface is subject to ligand
independent- vs dependent- regulation.
By developing a novel panel of rabbit monoclonal antibodies
specific to the hEPOR, and through analyses of the endogenous
EPOR expression in an EPO- dependent human erythroid
progenitor cell model, we first show that an EPOR-68K form
corresponds to a core- glycosylated apparent intracellular EPOR
pool; and that this pool increases in levels when EPO is limiting.
Upon further sustained limiting of EPO, an EPOR-70K form is
generated, which (unlike EPOR-68K) is indicated to then rapidly
convert upon EPO exposure to an activated EPOR-72K species.
(Interestingly, quantitative RT-PCR analyses of EPOR transcript
levels rule out up-modulation at this level as a potential underlying
mechanism) (Figure S8). Here, novel information generated is
several-fold. The finding that expression levels of intracellular and
apparent cell surface EPOR forms flux in ligand-dependent
fashions first is insightful. Specifically, this is unlike the majority of
growth factor receptors which typically maintain at least moderate
pools of mature cell surface receptor forms during ligand-
exposure. In studies of cells and tissues that have been exposed
to EPO, lack of insight into these EPOR properties can
unwittingly skew interpretations (for example, regarding the
presence vs absence of EPOR’s among candidate target cells).
For apparent intracellular species, interesting questions also are
raised as to what specific post-translational features may
distinguish EPOR-68K from EPOR-70K forms (and which might
possibly affect cell surface translocation). In addition, certain prior
studies of the EPOR in Friend virus transformed MEL cells [46],
or non-erythroid cells ectopically EPOR forms [18] have
implicated the occurrence of large pools of intracellular EPOR’s.
This may relate to viral gp55 plus EPOR interactions and/or
consequences of EPOR overexpression – High-level intracellular
EPOR pools presently have not been observed in UT7epo
erythroid progenitor cells (under any conditions).
A second major aspect of the present studies addresses the
extent to which inward trafficking of EPOR’s might be ligand -
independent vs -dependent. In particular, recent studies by Becker
and co-workers [18] have suggested that ligand-independent
EPOR trafficking may be a prime property of the EPOR system,
and that this property may allow for linear integration of EPOR
signals over a broad range of ligand concentrations. In contrast,
the present studies of endogenous EPOR internalization in EPO-
dependent UT7epo human erythroid progenitor cells strongly
argue for sharply ligand- dependent EPOR expression (and
turnover) routes. This finding is based on both flow cytometry, and
western blot analyses of mature EPOR forms. Furthermore, this is
to the extent that cells when cultured in EPO express only nominal
levels of cell surface EPOR’s. Conversely, when EPO becomes
limiting, endogenous EPOR forms become substantially up-
modulated at the cell surface. This basic aspect of EPOR
trafficking has been a matter of controversy, and is non-trivial
for considerations of ligand pharmacokinetics, and responses of
EPOR’s and target cells to physiological 1000-fold fluxes in EPO
levels [18]. Factors that may contribute to apparently disparate
results and/or interpretations for ligand-modulated EPOR
trafficking merit brief discussion. One may involve effects of
EPOR epitope- tagging as frequently employed to overcome
limiting features of available EPOR antibodies. Our laboratory
was among the first to employ this approach for the EPOR in the
form of an N-terminal HAI tag [47], and recently we have
alternatively incorporated a FLAG tag at the hEPOR’s C-
terminus. Unfortunately, each modification compromises EPOR
biological activity (i.e., EPO-dependenrt cell growth) several- fold
as assessed in BaF3, FDCW2 and/or UT7epo cells (data not
shown). This complication provided impetus for our development
of new EPOR antibodies with improved properties. A second may
relate to possibly altered trafficking if/when EPOR’s are
ectopically over-expressed. Third, analyses of EPOR trafficking
in non-erythroid or non-hematopoietic cells also may be affected
in unpredictable ways by heterologous factors.
The present studies also consider cell surface expression,
activation and internalization properties of representative C-
terminal truncated EPOR forms that have been described among
PFCP patients [48]. Each form presently studied harbors a
translational stop mutation within exon-8. One, G5881T, gives
rise to an EPOR-T392 form [13]; and the other, G1251T, to an
EPOR-T374 form [14]. In addition, each lacks 7 of 9 cytoplasmic
phosphotyrosine motifs for signal transduction factor recruitment
[13,35] as well as the majority of lysine sites for potential
ubiquitination. Also lacking is a proposed cytoplasmic binding
motif for a BTRC E3 ubiquitin ligase [20]. One hypothesis
advanced for enhanced functional attributes of EPOR-T alleles
has involved a prediction that such truncated receptor forms might
be substantially compromised in internalization capacities (and
consequently may reside persistently on the surface of erythroid
progenitors) [13,14,15,48,49]. Recent studies of mutated EPOR
alleles in transfected gamma-2A and BaF3 cells also are consistent
with this notion [18,19]. As presently studied in EPO-dependent
erythroid progenitors, however, internalization rates for truncated
EPOR-T forms were attenuated by only ,25% (see supporting
data, Figure S9). In exponentially growing erythroid progenitors, it
nonetheless was apparent that truncated EPOR-T392 and EPOR-
T374 forms accumulate as mature species at levels greater than
observed for the wt-EPOR. One interpretation of these results is
that hyperallelic activities of truncated EPOR forms may depend
on attenuated internalization (by speculation), together with
possibly attenuated transit through endosomes and/or proteo-
somes. In addition, these defects are exerted most strikingly under
physiological conditions of exponential growth. By analogy to
recent findings in the JAK kinase- linked IL7R and IL5R systems,
HGF receptor activation may involve (or depend upon) early
endosome entry [22,23]. If this proves to be the case for the
EPOR, then attenuated EPOR-T endosomal transit might also
contribute to sustained activation. Consistent with this interpre-
tation is an observed sustained activation of PY-EPOR-T forms
(together with JAK2).
Figure 8. In exponentially growing erythroid progenitors, EPOR-T-392 and EPOR-T-374 accumulate, and decrease endogenous
wt-EPOR expression. A] UT7-wtEPOR, UT7-EPOR-T392 and UT7-EPOR-T374 cells were cultured in EPO at either 0.3 or 3 U/mL. Levels of EPOR
expression in directly prepared lysates then were assessed via western blotting. B] EPO dose-dependent increases in truncated EPOR-T-392
expression, vs EPO dose-dependent decreases in wild-type EPOR expression– For the above western blot analyses, quantitative imaging illustrates
converse effects of EPO on expression levels of WT-EPOR vs EPOR-T-392 receptors. C] In erythroid progenitor cells expressing truncated EPOR forms,
heightened EPO levels lead to marked decreases in wild-type EPOR levels– For the above western blot analyses, quantitative imaging illustrates clear
inhibitory effects of EPOR-T392, and EPOR-T-374 expression on wild-type EPOR levels. D] Truncated alleles EPOR-T-392 and EPOR-T-374 each exhibit
clear EPO dose-dependent turnover to low- Mr EPOR-T species (*,**).
doi:10.1371/journal.pone.0029064.g008
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of truncated EPOR alleles on the expression of the endogenous
EPO receptor. (Notably, truncated EPOR alleles typically are co-
expressed together with a normal EPOR allele in primary familial
and congenital polycythemia patients) [14,15,48]. In particular,
when cells were maintained in EPO, EPOR-T expression resulted
Figure 9. In exponentially growing erythroid progenitor cells, mature EPOR-T forms, unlike mature wild-type EPOR’s, become
hyper-phosphorylated. A] UT7-wtEPOR, UT7-EPOR-T392 and UT7-EPOR-T374 cells were cultured in EPO at either 0.3 or 3 U/mL (as detailed above,
legend to Figure 8). Levels of PY-EPOR then were assessed via western blotting and also determined quantitatively (lower panel). B] Left panel: In the
above cells (samples), levels of PY-JAK2 also were analyzed. Right panel: Heightened EPO-dependent expansion of UT7-EPOR-T392 cells. UT7epo cells
expressing the wtEPOR or EPOR-T-392 at matched levels were cultured in EPO at the indicated concentrations, and at 48 hours viable cell numbers
were determined.
doi:10.1371/journal.pone.0029064.g009
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mechanisms might mediate this effect. First, when heterodimer-
ized with truncated EPOR forms, the endogenous EPOR may be
co-internalized but more readily processed (via C-terminal sub-
domains) upon entering endosomes. Second, during outward
trafficking, JAK2 chaperone effects, and/or EPOR processing
may be affected. In support of this notion, EPOR-T effects on
endogenous EPOR levels appear to also include decreases in
EPOR-68K forms. Via either (or both) route(s), decreases in levels
of wild-type EPOR’s in erythroid progenitors of polycythemia
patients translate to an increased escape of EPOR-JAK2
complexes from negative-feedback factors (as recruited via EPOR
C-terminal domains). For other HGFR’s that occur as truncated
alleles (e.g., MPL, GCSFR) [10,11,12] it should be of significant
interest to discover possible parallels in dysregulation in likewise
clinically meaningful contexts.
A final notable advancement of the present study involves
properties and utilities of our novel anti-EPOR antibodies per se.
Antibody IC-c1.1 exhibits high specificity (and sensitivity) in
western blotting; and antibody EC-c38.5 is proposed to possess
uniquely advantageous properties for flow cytometry. Specific
immunoprecipitation of EPOR’s by antibodies IC-c1.1, IC-c34.11
and EC-c38.5 also is illustrated. In addition, promising utility of
ICD antibody IC-c1.1 in IHC is demonstrated. Together, our new
EPOR antibody panel therefore represents a valuable new tool set
for investigations of the intriguing and clinically important
properties of the EPOR.
Supporting Information
Figure S1 Apparent specificities of additional anti-
EPOR ICD antibodies (and of the commercial antibody
M-20). Western blots were prepared using the cell line lysate
samples indexed. Blots were then probed with the alternate anti-
EPOR antibodies indicated. For comparison, data in the lower
panel are provided for commercial antibody M-20.
(TIF)
Figure S2 Detection of EPOR molecular species by anti-
EPOR antibody IC-c1.1 are uniformly blocked by co-
incubation with immunizing peptide. A single gel and
western blot was loaded in duplicate (left and right aspects) with
the indicated HL60 cell and UT7epo cell lysates. For the half-blot
in the lower panel, primary antibody IC-c1.1 was incubated with
immunizing peptide (1 mM) during exposure to blotted proteins.
Blots were co-processed in parallel. Loading controls are beta-
tubulin (for each half blot).
(TIF)
Figure S3 Specific immunoprecipitation of the endoge-
nous hEPOR from UT7epo cells by anti-EPOR antibod-
ies IC-c1.1, IC-c34.11 and EC-c38.5. UT7epo cells were
deprived of hematopoietic cytokines for 20 hours. Lysates were
then prepared (Igepal, 0.4%) cleared, and incubated for 4 hours
with 4 mg of anti-EPOR antibodies (or rabbit IgG). Immune
complexes then were retrieved (Protein-A Sepharose CL4B),
washed, eluted and analyzed by western blotting with anti-EPOR
antibody IC-c1.1.
(TIF)
Figure S4 Specific immunohistochemical assays of the
human EPOR. A] To allow for optimization of IHC staining
(and related IHC preparations) the wild-type EPOR was
ectopically expressed at limited levels in EPOR negative myeloid
HL60 cells (i.e., levels estimated by western blotting to be
approximately 5-fold below those of the endogenous EPOR in
UT7epo cells). IHC sections then were prepared as detailed in
Methods, and sections were stained with an HRP- coupled anti-
rabbit IgG second antibody. B] Using anti-EPOR antibody IC-
c1.1, specific IHC assay of the endogenous EPOR in UT7epo cells
also was accomplished.
(TIF)
Figure S5 Western blot (and parallel RT-PCR) assays of
the EPOR expression in human bone marrow CD34
pos
progenitor- derived (pro)erythroblasts. Erythroid cells
were expanded from human bone marrow CD34
pos progenitors
in SP34ex medium. At day 10 of expansion, TFR1
high (TFR,
transferrin receptor) cells were highly represented, and (via
MACS) were enriched for GPA
low and GPA
high sub-populations
(lower panel C). EPOR expression levels in each erythroid
progenitor pool then were assayed by western blotting (panel A)
and quantitative RT-PCR (panel B).
(TIF)
Figure S6 Ectopic expression of EPOR’s in UT7epo cells
at levels approximating endogenous EPOR levels.
UT7epo cells were transduced with VSVG-packaged pMSCVneo
viruses encoding hEPOR constructs or no cDNA inset (empty
vector). MOI’s were varied in order to determine transduction
conditions that provided for the expression of EPOR alleles at
physiological levels. Western blotting was with anti-EPOR
Figure 10. Proposed model for mechanisms that contribute to
gain-of-function phenotypes exhibited by truncated PFCP
EPOR alleles. For truncated EPOR alleles harbored by polycythemia
patients (as diagramed) a combined set of mechanisms are proposed to
lead to dysregulation of EPO/EPOR signaling (by truncated alleles, and
the co-expressed wild-type EPOR). 1- Unlike the wild-type EPOR, EPOR-T
alleles do not appear to accumulate within intercellular pools. 2- EPOR-T
internalization is indicate to be modestly to moderately attenuated. 3-
Activation of EPOR-T alleles is clearly heightened. 4- Attenuated inward
trafficking also may include prolonged residence within an early
lysosomal compartment. 5- As proposed previously, the truncation of C-
terminal domains likely results in uncoupling from negative feed-back
effects of SOCS1/3 and/or SHP1. 6- Via as yet unresolved mechanisms,
expression (and ligation) of truncated EPOR alleles also results in
decreased expression levels of the wild-type EPOR (as co-expressed
among polycythemia patients with EPOR-T alleles).
doi:10.1371/journal.pone.0029064.g010
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stably transduced UT7epo-wtEPOR cells. (Also see Figures 6
and 7).
(TIF)
Figure S7 Relative mobilities (in SDS PAGE) of specific
EPOR molecular weight species observed upon the
expression of the wild-type EPOR and EPOR-T-392 in
UT7epo cells. For corresponding western blots, please see
Figure 6B.
(TIF)
Figure S8 EPO withdrawal does not lead to increases in
EPOR transcript levels. Exponentially growing UT7epo cells
were plated at 8610
5 cells/mL in the absence of hematopoietic
cytokines. At 0, 6, 12 and 24 hours of culture, RNA was directly
isolated, EPOR transcript levels then were determined by
quantitative RT-PCR. Graphed values are cycle numbers
normalized for beta-actin (which varied less than 2 cycles overall
among samples).
(TIF)
Figure S9 Truncated EPOR alleles harbored by polycy-
themia patients are moderately attenuated in ligand-
induced internalization. A] Attenuated internalization of
EPOR-T-392 and EPOR-T-374 alleles – UT7epo cells were
transduced (at limiting MOI’s) with a pMSCVneo vector encoding
the wt-EPOR, EPOR-T-392 or EPOR-T-374. For cells expressing
each EPOR form at low, matched levels, ligand-induced rates of
EPOR internalization were determined by flow cytometry. This
involved EPO withdrawal (20 hours) plus subsequent EPO
challenge at either 1 U/mL or 3 U/mL. At 0, 10, 30 and
90 minutes of EPO exposure, levels of cell surface EPOR’s were
assayed. Truncated EPOR forms underwent internalization, but
with apparently attenuated kinetics. B] Primary flow cytometry
data are also illustrated (90 minute time points).
(TIF)
Acknowledgments
Supporting contributions by Affymax, Inc. (Palo Alto, CA) and Takeda
Global Research & Development Center, Inc. (Deerfield, IL) are gratefully
acknowledged. The authors also wish to acknowledge strong expert
technical assistance provided by Ruth Asch and Edward Jachimowicz
(MMCRI).
Author Contributions
Conceived and designed the experiments: SS RV AP KL RBM PRY MO
PJS JMG DMW. Performed the experiments: SS RV AP KL RBM PRY
MO PJS JMG DMW. Analyzed the data: SS RV AP KL RBM PRY MO
PJS JMG DMW. Contributed reagents/materials/analysis tools: SS RV
AP KL RBM PRY MO PJS JMG DMW. Wrote the paper: SS RV AP KL
RBM PRY MO PJS JMG DMW.
References
1. Metcalf D (2008) Hematopoietic cytokines. Blood 111: 485–491.
2. Perugini M, Varelias A, Sadlon T, D’Andrea RJ (2009) Hematopoietic growth
factor mimetics: from concept to clinic. Cytokine Growth Factor Rev 20: 87–
94.
3. Baker SJ, Rane SG, Reddy EP (2007) Hematopoietic cytokine receptor
signaling. Oncogene 26: 6724–6737.
4. Pedersen M, Ronnstrand L, Sun J (2009) The c-Kit/D816V mutation eliminates
the differences in signal transduction and biological responses between two
isoforms of c-Kit. Cell Signal 21: 413–418.
5. Chen J, Olsen J, Ford S, Mirza S, Walker A, et al. (2009) A new isoform of
interleukin-3 receptor {alpha} with novel differentiation activity and high
affinity binding mode. J Biol Chem 284: 5763–5773.
6. Martinez-Nunez RT, Louafi F, Sanchez-Elsner T (2011) The interleukin 13 (IL-
13) pathway in human macrophages is modulated by microRNA-155 via direct
targeting of interleukin 13 receptor alpha1 (IL13Ralpha1). J Biol Chem 286:
1786–1794.
7. Sasson SC, Smith S, Seddiki N, Zaunders JJ, Bryant A, et al. (2010) IL-7
receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other
B-cell derived neoplasms and correlates with expression of proliferation and
survival markers. Cytokine 50: 58–68.
8. Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, et al. (2009) Monoclonal
antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates
human acute myeloid leukemic stem cells. Cell Stem Cell 5: 31–42.
9. Jiao B, Wu CF, Liang Y, Chen HM, Xiong SM, et al. (2009) AML1-ETO9a is
correlated with C-KIT overexpression/mutations and indicates poor disease
outcome in t(8;21) acute myeloid leukemia-M2. Leukemia 23: 1598–1604.
10. Teofili L, Giona F, Torti L, Cenci T, Ricerca BM, et al. (2010) Hereditary
thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic
risk, splenomegaly and progression to bone marrow fibrosis. Haematologica 95:
65–70.
11. Germeshausen M, Skokowa J, Ballmaier M, Zeidler C, Welte K (2008) G-CSF
receptor mutations in patients with congenital neutropenia. Curr Opin Hematol
15: 332–337.
12. Liu F, Kunter G, Krem MM, Eades WC, Cain JA, et al. (2008) Csf3r mutations
in mice confer a strong clonal HSC advantage via activation of Stat5. J Clin
Invest 118: 946–955.
13. Arcasoy MO, Karayal AF (2005) Erythropoietin hypersensitivity in primary
familial and congenital polycythemia: role of tyrosines Y285 and Y344 in
erythropoietin receptor cytoplasmic domain. Biochim Biophys Acta 1740:
17–28.
14. Perrotta S, Cucciolla V, Ferraro M, Ronzoni L, Tramontano A, et al. (2010)
EPO receptor gain-of-function causes hereditary polycythemia, alters CD34 cell
differentiation and increases circulating endothelial precursors. PLoS One 5:
e12015.
15. Huang LJ, Shen YM, Bulut GB (2010) Advances in understanding the
pathogenesis of primary familial and congenital polycythaemia. Br J Haematol
148: 844–852.
16. Jegalian AG, Wu H (2002) Differential roles of SOCS family members in EpoR
signal transduction. J Interferon Cytokine Res 22: 853–860.
17. Sarna MK, Ingley E, Busfield SJ, Cull VS, Lepere W, et al. (2003) Differential
regulation of SOCS genes in normal and transformed erythroid cells. Oncogene
22: 3221–3230.
18. Becker V, Schilling M, Bachmann J, Baumann U, Raue A, et al. (2010)
Covering a broad dynamic range: information processing at the erythropoietin
receptor. Science 328: 1404–1408.
19. Sulahian R, Cleaver O, Huang LJ (2009) Ligand-induced EpoR internalization
is mediated by JAK2 and p85 and is impaired by mutations responsible for
primary familial and congenital polycythemia. Blood 113: 5287–5297.
20. Meyer L, Deau B, Forejtnikova H, Dumenil D, Margottin-Goguet F, et al.
(2007) beta-Trcp mediates ubiquitination and degradation of the erythropoietin
receptor and controls cell proliferation. Blood 109: 5215–5222.
21. Bulut GB, Sulahian R, Ma Y, Chi NW, Huang LJ (2011) Ubiquitination
regulates the internalization, endolysosomal sorting, and signaling of the
erythropoietin receptor. J Biol Chem 286: 6449–6457.
22. Lei JT, Martinez-Moczygemba M (2008) Separate endocytic pathways regulate
IL-5 receptor internalization and signaling. J Leukoc Biol 84: 499–509.
23. Henriques CM, Rino J, Nibbs RJ, Graham GJ, Barata JT (2010) IL-7 induces
rapid clathrin-mediated internalization and JAK3-dependent degradation of IL-
7Ralpha in T cells. Blood 115: 3269–3277.
24. Neumann D, Wikstrom L, Watowich SS, Lodish HF (1993) Intermediates in
degradation of the erythropoietin receptor accumulate and are degraded in
lysosomes. J Biol Chem 268: 13639–13649.
25. Komatsu N, Yamamoto M, Fujita H, Miwa A, Hatake K, et al. (1993)
Establishment and characterization of an erythropoietin-dependent subline, UT-
7/Epo, derived from human leukemia cell line, UT-7. Blood 82: 456–464.
26. Sathyanarayana P, Dev A, Fang J, Houde E, Bogacheva O, et al. (2008) EPO
receptor circuits for primary erythroblast survival. Blood 111: 5390–5399.
27. Dev A, Fang J, Sathyanarayana P, Pradeep A, Emerson C, et al. (2010) During
EPO or anemia challenge, erythroid progenitor cells transit through a selectively
expandable (pro)erythroblast pool. Blood.
28. Broudy VC, Lin N, Brice M, Nakamoto B, Papayannopoulou T (1991)
Erythropoietin receptor characteristics on primary human erythroid cells. Blood
77: 2583–2590.
29. Elliott S, Busse L, McCaffery I, Rossi J, Sinclair A, et al. (2010) Identification of
a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of
low levels of EpoR in cells. J Immunol Methods 352: 126–139.
30. Elliott S, Busse L, Bass MB, Lu H, Sarosi I, et al. (2006) Anti-Epo receptor
antibodies do not predict Epo receptor expression. Blood 107: 1892–1895.
31. Chun J, Shapovalova Z, Dejgaard SY, Presley JF, Melancon P (2008)
Characterization of class I and II ADP-ribosylation factors (Arfs) in live cells:
GDP-bound class II Arfs associate with the ER-Golgi intermediate compartment
independently of GBF1. Mol Biol Cell 19: 3488–3500.
32. Usenko T, Eskinazi D, Correa PN, Amato D, Ben-David Y, et al. (2007)
Overexpression of SOCS-2 and SOCS-3 genes reverses erythroid overgrowth
Dynamic Regulation of EPOR Pools
PLoS ONE | www.plosone.org 16 January 2012 | Volume 7 | Issue 1 | e29064and IGF-I hypersensitivity of primary polycythemia vera (PV) cells. Leuk
Lymphoma 48: 134–146.
33. Hookham MB, Elliott J, Suessmuth Y, Staerk J, Ward AC, et al. (2007) The
myeloproliferative disorder-associated JAK2 V617F mutant escapes negative
regulation by suppressor of cytokine signaling 3. Blood 109: 4924–4929.
34. Wickrema A, Chen F, Namin F, Yi T, Ahmad S, et al. (1999) Defective
expression of the SHP-1 phosphatase in polycythemia vera. Exp Hematol 27:
1124–1132.
35. Wojchowski DM, Sathyanarayana P, Dev A (2010) Erythropoietin receptor
response circuits. Curr Opin Hematol 17: 169–176.
36. Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, et al. (1993) JAK2
associates with the erythropoietin receptor and is tyrosine phosphorylated and
activated following stimulation with erythropoietin. Cell 74: 227–236.
37. Seubert N, Royer Y, Staerk J, Kubatzky KF, Moucadel V, et al. (2003) Active
and inactive orientations of the transmembrane and cytosolic domains of the
erythropoietin receptor dimer. Mol Cell 12: 1239–1250.
38. Sasaki A, Yasukawa H, Shouda T, Kitamura T, Dikic I, et al. (2000) CIS3/
SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor
and JAK2. J Biol Chem 275: 29338–29347.
39. Liu L, Damen JE, Ware M, Hughes M, Krystal G (1997) SHIP, a new player in
cytokine-induced signalling. Leukemia 11: 181–184.
40. Macdougall IC, Rossert J, Casadevall N, Stead RB, Duliege AM, et al. (2009) A
peptide-based erythropoietin-receptor agonist for pure red-cell aplasia.
N Engl J Med 361: 1848–1855.
41. Carraway MS, Suliman HB, Jones WS, Chen CW, Babiker A, et al. (2010)
Erythropoietin activates mitochondrial biogenesis and couples red cell mass to
mitochondrial mass in the heart. Circ Res 106: 1722–1730.
42. Tong Z, Yang Z, Patel S, Chen H, Gibbs D, et al. (2008) Promoter
polymorphism of the erythropoietin gene in severe diabetic eye and kidney
complications. Proc Natl Acad Sci U S A 105: 6998–7003.
43. Choi D, Schroer SA, Lu SY, Wang L, Wu X, et al. (2010) Erythropoietin
protects against diabetes through direct effects on pancreatic beta cells. J Exp
Med 207: 2831–2842.
44. Tong W, Zhang J, Lodish HF (2005) Lnk inhibits erythropoiesis and Epo-
dependent JAK2 activation and downstream signaling pathways. Blood 105:
4604–4612.
45. Forejtnikova H, Vieillevoye M, Zermati Y, Lambert M, Pellegrino RM, et al.
(2010) Transferrin receptor 2 is a component of the erythropoietin receptor
complex and is required for efficient erythropoiesis. Blood 116: 5357–5367.
46. Yoshimura A, D’Andrea AD, Lodish HF (1990) Friend spleen focus-forming
virus glycoprotein gp55 interacts with the erythropoietin receptor in the
endoplasmicreticulumandaffectsreceptormetabolism.ProcNatlAcadSciUSA
87: 4139–4143.
47. He TC, Zhuang H, Jiang N, Waterfield MD, Wojchowski DM (1993)
Association of the p85 regulatory subunit of phosphatidylinositol 3-kinase with
an essential erythropoietin receptor subdomain. Blood 82: 3530–3538.
48. Patnaik MM, Tefferi A (2009) The complete evaluation of erythrocytosis:
congenital and acquired. Leukemia 23: 834–844.
49. Motohashi T, Nakamura Y, Osawa M, Hiroyama T, Iwama A, et al. (2001)
Increased cell surface expression of C-terminal truncated erythropoietin
receptors in polycythemia. Eur J Haematol 67: 88–93.
Dynamic Regulation of EPOR Pools
PLoS ONE | www.plosone.org 17 January 2012 | Volume 7 | Issue 1 | e29064